secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-038061
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron submits NDA for imetelstat in lower risk MDS; Q2 cash $400.2M
-------------------------------------------------------------------

- Submitted first NDA for a telomerase inhibitor (imetelstat) to FDA for lower risk MDS in June 2023.
- Cash, equivalents and securities of $400.2M as of June 30; expects to fund operations through end of 2025.
- Reaffirmed FY2023 GAAP total expense guidance of $210M–$220M; non-GAAP $200M–$210M.
- IMpactMF Phase 3 trial in myelofibrosis enrolled >40%; interim analysis expected H1 2025.
- Appointed Scott Samuels as EVP, Chief Legal Officer and Corporate Secretary effective August 1, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/0000950170-23-038061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/gern-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-038061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer